<!DOCTYPE HTML>
<html>
<head>
  <meta charset="utf-8">
  
  <title>ymtang&#39;s blog</title>
  <meta name="author" content="ymtang">
  
  <meta name="description" content="CrystalarthropathyGoutDeposition of monosodium urate crystals in the joint, causing painful arthritis

Due to over-production/under-secretion of uric ">
  
  
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">

  
  <meta property="og:site_name" content="ymtang&#39;s blog">

  
    <meta property="og:image" content="undefined">
  

  <link href="/blog/favicon.png" rel="icon">
  <link rel="alternate" href="/blog/atom.xml" title="ymtang&#39;s blog" type="application/atom+xml">
  <link rel="stylesheet" href="/blog/css/style.css" media="screen" type="text/css">
  <!--[if lt IE 9]><script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script><![endif]-->
  

</head>
</html>

<body>
  <header id="header" class="inner"><div class="alignleft">
  <h1><a href="/blog/">ymtang&#39;s blog</a></h1>
  <h2><a href="/blog/"></a></h2>
</div>
<nav id="main-nav" class="alignright">
  <ul>
    
      <li><a href="/blog/">Home</a></li>
    
      <li><a href="/blog/archives">Archives</a></li>
    
      <li><a href="/blog/about">About</a></li>
    
      <li><a href="/blog/revision">Revision</a></li>
    
  </ul>
  <div class="clearfix"></div>
</nav>
<div class="clearfix"></div>
</header>
  <div id="content" class="inner">
    <div id="main-col" class="alignleft"><div id="wrapper"><article class="page">
  
  <div class="post-content">
    <header>
      
      
  
    <h1 class="title"></h1>
  

    </header>
    <div class="entry">
      
        <h1 id="Crystalarthropathy"><a href="#Crystalarthropathy" class="headerlink" title="Crystalarthropathy"></a>Crystalarthropathy</h1><h2 id="Gout"><a href="#Gout" class="headerlink" title="Gout"></a>Gout</h2><p>Deposition of monosodium urate crystals in the joint, causing painful arthritis</p>
<ul>
<li>Due to over-production/under-secretion of uric acid</li>
</ul>
<p>Uric acid - a purine base derived from breakdown of purines (2 rings)</p>
<ul>
<li>adenine, guanine, hypoxanthine<ul>
<li>Xanthine oxidase acts on hypoxanthine &amp; xanthine to form uric acid<ul>
<li>Allopurinol (inhibits xanthine oxidase)</li>
</ul>
</li>
</ul>
</li>
<li>Normal uric acid (urate) concentration<ul>
<li>Male - 0.25 - 0.42 mmol/L</li>
<li>Female - 0.18 - 0.38 mmol/L</li>
</ul>
</li>
<li>Uric acid solubility at 0.4 mmol/L</li>
<li>Crystallisation occurs &gt; 0.4 mmol/L</li>
</ul>
<p>Dietary sources of uric acid</p>
<ul>
<li>Seafood, meat, alcohol (especially beer)</li>
</ul>
<p>De novo purine synthesis pathway (i.e. making new purines)<br>PRPP - phosphoribosyl pyrophosphate</p>
<ul>
<li>Promotes uric acid production</li>
</ul>
<p>Salvage pathway (i.e. makes the purine base become nucleotides instead of going toward uric acid synthesis)<br>APRT - adenine phosphoribosyltransferase</p>
<ul>
<li>Inhibits uric acid production</li>
<li>Reciver purine bases for use as purine nucleotides</li>
</ul>
<h2 id="Lesch-Nyhan-Syndrome-juvenile-gout"><a href="#Lesch-Nyhan-Syndrome-juvenile-gout" class="headerlink" title="Lesch-Nyhan Syndrome (juvenile gout)"></a>Lesch-Nyhan Syndrome (juvenile gout)</h2><p>X-linked recessive<br>Gene mutation leads to deficient HGPRT - hypoxanthine-guanine phosphoribosyltransferase</p>
<ul>
<li>HGPRT responsible for salvage pathway</li>
</ul>
<p>Promotion of de novo pathway with PRPP</p>
<ul>
<li>Serious CNS effects<ul>
<li>mental retardation</li>
<li>growth retardation</li>
<li>choreoathetosis (involuntary movements - twisting, writhing)</li>
<li>spasticity</li>
<li>self-mutilation<br>Neurons have low levels of de novo purine synthesis enzymes</li>
</ul>
</li>
</ul>
<h2 id="Benefits-of-uric-acid"><a href="#Benefits-of-uric-acid" class="headerlink" title="Benefits of uric acid"></a>Benefits of uric acid</h2><p>Anti-oxidant effect</p>
<h2 id="Interaction-of-urate-crystals-and-immune-system"><a href="#Interaction-of-urate-crystals-and-immune-system" class="headerlink" title="Interaction of urate crystals and immune system"></a>Interaction of urate crystals and immune system</h2><ul>
<li>low grade inflammation (raised WCC in synovial fluid) between flares</li>
<li>Escalates during flares</li>
<li>Crystals:<ul>
<li>Recognised by TLRs</li>
<li>Phagocytosed by macrophages</li>
<li>Stimulates IL-1B -&gt; TNF, IL-6, neutrophil chemottractants<ul>
<li>Inflammation</li>
</ul>
</li>
<li>Bone lesions (from arthritis) - activation of macrophages/osteoclasts</li>
</ul>
</li>
</ul>
<h2 id="Clinical-Features"><a href="#Clinical-Features" class="headerlink" title="Clinical Features"></a>Clinical Features</h2><h3 id="Early-gout"><a href="#Early-gout" class="headerlink" title="Early gout"></a>Early gout</h3><ul>
<li>monoarticular</li>
<li>rapid onset, severe pain</li>
<li>1st MTP (podagra - big toe pain) or mid-foot</li>
</ul>
<h3 id="Late-gout"><a href="#Late-gout" class="headerlink" title="Late gout"></a>Late gout</h3><ul>
<li>Tophi</li>
<li>Oligoarticular attacks (multiple joints affected)<ul>
<li>Knees, writs, fingers, elbows</li>
</ul>
</li>
<li>Prolonged episodes -&gt; incomplete resolution</li>
</ul>
<h2 id="Diagnosis-distinguish"><a href="#Diagnosis-distinguish" class="headerlink" title="Diagnosis (distinguish)"></a>Diagnosis (distinguish)</h2><p><strong>Joint aspiration &amp; synovial fluid analysis</strong></p>
<ul>
<li>Gout - identify monosodium urate monohydrate<ul>
<li>Needle-shaped</li>
<li>negatively birefringent<ul>
<li>Corticosteroid crystals such as from betamethasone look like MSU crystals</li>
</ul>
</li>
</ul>
</li>
<li>Pseudogout - identify calcium pyrophosphate<ul>
<li>Rhomboidal</li>
<li>positively birefringent</li>
</ul>
</li>
<li>Septic arthritis – excluded with synovial fluid analysis from aspiration</li>
<li>Other types of inflammatory arthritis (RA)</li>
</ul>
<p><strong>Serum urate not useful for dx</strong></p>
<ul>
<li>Up to 40% patients with acute gout have serum urate below crystallisation threshold of 0.42mmol/L</li>
<li>Only 20% patients above 0.42mmol/L threshold develop gout</li>
</ul>
<p><strong>X-ray</strong></p>
<ul>
<li>Insensitive</li>
<li>Soft tissue swelling</li>
<li>Cloud-like calcification</li>
<li>Preservation of joint space</li>
<li>Erosion present (commonly mistaken for RA)</li>
</ul>
<p><u><em>Crystal arthritis &amp; sepsis can co-exist!</em></u></p>
<h2 id="Management-of-gout"><a href="#Management-of-gout" class="headerlink" title="Management of gout"></a>Management of gout</h2><h3 id="Controlling-uric-acid-levels-not-just-with-gout"><a href="#Controlling-uric-acid-levels-not-just-with-gout" class="headerlink" title="Controlling uric-acid levels (not just with gout)"></a>Controlling uric-acid levels (not just with gout)</h3><blockquote>
<p>Not urgent, but long-term commitment for gout patients</p>
<ul>
<li>Indications for urate-lowering therapy:<ul>
<li>tophi</li>
<li>chronic joint, tendon damage from gout<ul>
<li>erosions (x-ray)</li>
<li>chronic gouty arthropathy (clinical evidence)</li>
<li>persistent symptoms instead of intermittent</li>
<li>multiple joint involvement</li>
</ul>
</li>
<li>chronic kidney disease (stage II)</li>
<li>Hx of kidney stones</li>
<li>Patient’s choice<ul>
<li>based on frequency (&gt;= 2 attacks a year), severity &amp; duration of gout attacks</li>
</ul>
</li>
</ul>
</li>
<li>Target uric acid levels<ul>
<li>&lt; 0.36 mmol/L<ul>
<li>This number is well below all laboratory reference ranges</li>
</ul>
</li>
<li>&lt; 0.30 mmol/L<ul>
<li>Patients with tophi or with evidence of high urate crystal burden</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Prevent acute gout (TARGET LEVELS of uric acid &lt; 0.36 mmol/L)<br>Eliminate tophi – deposits of monosodium urate (cause inflammation -&gt; arthritis)</p>
<ul>
<li>Block uric acid synthesis<ul>
<li>Allopurinol - binds irreversibly to xanthine oxidase (suicide inhibition)</li>
<li>Febuxostat - (non-purine inhibitor of xanthine oxidase)</li>
</ul>
</li>
<li>Promote urinary excretion of uric acid</li>
<li>Convert to allantoin (highly water soluble)<ul>
<li>In other animals, uric acid is converted to allantoin via uricase</li>
<li>Humans lack uricase<ul>
<li>rasburicase - derived from fungi</li>
</ul>
</li>
</ul>
</li>
</ul>
</blockquote>
<ul>
<li><em>Tumour lysis syndrome</em> - when high levels of apoptosis occurs during chemotherapy, cells release their contents, plasma urate levels increased</li>
<li>Reverse hyperuricaemia in ischaemic heart disease</li>
</ul>
<h3 id="Pharmacotherapy"><a href="#Pharmacotherapy" class="headerlink" title="Pharmacotherapy"></a>Pharmacotherapy</h3><p><strong>NSAIDs</strong></p>
<ul>
<li>acute attacks<ul>
<li>diclofenac, indometacin or other NSAIDs</li>
<li>NOT WITH ASPIRIN<ul>
<li>actually raises plasma urate levels at low doses<ul>
<li>inhibits uric acid secretion in renal tubules</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Contraindications<ul>
<li>Renal impairment</li>
<li>Cardiac/hepatic failure</li>
<li>Bleeding risk due to anti-coagulative effects</li>
<li>Peptic ulceration - COX-1 inhibition</li>
<li>Poorly controlled hypertension</li>
</ul>
</li>
</ul>
<p><strong>Colchicine (rarely used alone)</strong><br>Modulates pro-inflammatory &amp; anti-inflammatory processes  </p>
<ul>
<li>prevents microtubule assembly<ul>
<li>disrupts inflammasome activation</li>
<li>microtubule-based inflammatory cell chemotaxis<ul>
<li>leukocytes thus unable to migrate to sites of uric acid deposition, reducing inflammatory responses</li>
</ul>
</li>
</ul>
</li>
<li>disrupts generation of leukotrienes, cytokines</li>
<li>disrupts phagocytosis</li>
</ul>
<p><u>Colchicine in Acute gout</u></p>
<ul>
<li>Normal dosing (initial high dose of 1mg, half dose 0.5mg every 2-6 hours)<ul>
<li>high rates of GI toxicity</li>
</ul>
</li>
<li>Low dosing (initial higher dose of 1.2mg, half dose 0.6mg 1 hour later)<ul>
<li>reduced GI toxicity but relatively poor efficacy</li>
</ul>
</li>
<li>Prophylactic dose<ul>
<li>0.5mg twice daily</li>
</ul>
</li>
</ul>
<p><u>Colchicine toxicity</u></p>
<ul>
<li>nausea, diarrhoea, vomiting</li>
<li>acute myopathy, multi-system failure<ul>
<li>beware patients with renal failure</li>
<li>beware patients on drugs that inihibit cytochrome P450 3A4<ul>
<li>cyclosporin, pravastatin, azithromycin, clarithromycin</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><strong>Allopurinol (prophylactic)</strong><br>Lowers plasma urate by irreversibly binding to xanthine oxidase (suicide inhibition)  </p>
<ul>
<li>xanthine unable to be converted to uric acid</li>
<li>300mg/day will reach target level</li>
<li>600mg, 900mg in patients with normal renal function<ul>
<li>further decrease in serum urate<br>Useful for patients with recurrent gout attacks  </li>
</ul>
</li>
</ul>
<p><u>Severe allupurionol hypersensitivity</u></p>
<ul>
<li>1 in 1000</li>
<li>Occurs &lt; 6 weeks after starting allopurinol</li>
<li>Not associated with higher maintenance doses</li>
<li>Risk factors<ul>
<li>renal insufficiency (increased age)<ul>
<li>Start low dose (1.5mg per unit of eGFR daily)</li>
<li>Warn patient, monitor for hypersensitivity in first 6-12 weeks</li>
<li>Progressively increase dose until maximal effect reached</li>
</ul>
</li>
<li>Thiazide diuretic use</li>
<li>Initial high dose</li>
<li>HLA-B*58:01 (patients with GFR &lt; 60)<ul>
<li>Han Chinese/Thai/Korean extraction</li>
</ul>
</li>
</ul>
</li>
<li>Desensitisation to allopurinol<ul>
<li>oral dosing, increasing from minute amounts to 300mg/day over 30 days</li>
</ul>
</li>
</ul>
<p><strong>Probenecid (uricosuric)</strong></p>
<ul>
<li>increases renal urate clearance</li>
<li>Need good hydration, urine to be alkalinised<ul>
<li>Alkaline pH, urate less soluble, tend to crystallise in urine</li>
</ul>
</li>
<li>Requires renal sufficiency</li>
<li>Useful addition to allopurinol</li>
<li>Next option for patients intolerant to allopurinol</li>
</ul>
<p><strong>Febuxostat</strong></p>
<ul>
<li>Xanthine oxidase inhibitor - same function as allopurinol</li>
<li>Up to 80mg/day</li>
<li>Rapid oral absorption</li>
<li>Metabolised in liver</li>
<li>No dose modification in patients with moderate renal impairment</li>
<li>Good alternative for patients intolerant to allopurinol</li>
</ul>
<p><strong>Benzbromarone</strong></p>
<ul>
<li>increases renal urate clearance</li>
<li>Need good hydration, urine to be alkalinised<ul>
<li>Alkaline pH, urate less soluble, tend to crystallise in urine</li>
</ul>
</li>
<li>Requires renal sufficiency</li>
<li>REQUIRES CLOSE MONITORING OF LFTs<ul>
<li>Liver failure deaths occurred</li>
</ul>
</li>
<li>Potent uricosuric, can be added to allopurinol</li>
</ul>
<p><strong>Other uricosuric drugs (prophylactic)</strong><br>Sulfinpyrazone</p>
<p>Increased secretion of uric acid</p>
<ul>
<li><p>inhibit reabsorption at renal tubules</p>
</li>
<li><p>Fluid status IMPORTANT</p>
<ul>
<li>to prevent crystallisation in urine</li>
</ul>
</li>
</ul>
<p>Less effective &amp; more toxic than allopurinol</p>
<ul>
<li>Normally used when patient unable to tolerate allopurinol</li>
</ul>
<p><strong>Uricase derivatives – converts uric acid to water-soluble allantoin</strong><br><em>Rasburicase</em></p>
<ul>
<li>treat/prevent uric acid nephropathy in chemotherapy<ul>
<li>tumour lysis syndrome</li>
</ul>
</li>
<li>acts on BOTH soluble urate and urate crystals<ul>
<li>rapid reduction of tophi</li>
</ul>
</li>
<li>Expensive<ul>
<li>Short duration of action</li>
<li>Chance of allergy with repeated infusions</li>
</ul>
</li>
</ul>
<p><em>Pegloticase</em></p>
<ul>
<li>8mg every 2 weeks</li>
<li>effective at maintaining serum urate below target (up to 6 months)</li>
<li>Expensive<ul>
<li>Short duration of action</li>
<li>Chance of allergy with repeated infusions</li>
</ul>
</li>
</ul>
<p><strong>Corticosteroids &amp; gout</strong><br><u>Intra-articular steroid injection</u>  </p>
<ul>
<li>Options<ul>
<li>Betamethasone</li>
<li>Methylprednisolone</li>
<li>Triamcinolone</li>
</ul>
</li>
<li>Injected after joint aspiration done through the same needle<ul>
<li>Done with other therapy (e.g. colchicine 0.5mg twice, daily) as prophylaxis</li>
</ul>
</li>
</ul>
<p><u>Systemic corticosteroid delivery</u><br>Regime can be modified based on rapidity of response<br>Prednisone</p>
<ul>
<li>20mg/3 days -&gt; 15mg/3 days -&gt; 10mg/3 days -&gt; 5mg/3 days -&gt; 0mg<ul>
<li>Need to wean</li>
</ul>
</li>
<li>Consider:<ul>
<li>diabetic patients (hyperglycaemia)</li>
<li>co-existing sepsis (risk of immunosuppression)<ul>
<li>poor response</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><strong>Tetracosactrin (ACTH)</strong><br>Stimulates adrenal glands to produce &amp; release endogenous corticosteroids (cortisol)</p>
<ul>
<li>requires intact adrenal function (obviously)</li>
<li>endogenously reduce inflammation</li>
</ul>
<p>Test adrenal function/reserve before giving depot preparation (intramuscular)  </p>
<ul>
<li>DO NOT USE if patient is on chronic prednisone therapy</li>
<li>Contraindicated in diabetic patients – &#8657; corticosteroid leads to hyperglycaemia</li>
<li>Useful if patient will not follow-up<ul>
<li>Depot preparation - slow release, gradual absroption</li>
</ul>
</li>
</ul>
<p><strong>Biologic agents</strong><br>IL-1 inhibitors to suppress inflammation</p>
<ul>
<li>Canakinumab<ul>
<li>Effective but extremely expensive</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th><em>Drug</em></th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allopurinol</strong></td>
<td>- single daily dose</td>
<td>Poor at eliminating tophi</td>
</tr>
<tr>
<td></td>
<td>- works in renal failure</td>
<td></td>
</tr>
<tr>
<td><strong>Febuxostat</strong></td>
<td>- single daily dose</td>
<td>Long-term safety &amp; efficacy (<em>it’s a new drug</em>)</td>
</tr>
<tr>
<td></td>
<td>- reduced incidence of gouty ‘flares’</td>
<td></td>
</tr>
<tr>
<td><strong>Benzbromarone</strong></td>
<td>- Effective in renal impairment</td>
<td>- Liver toxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Promotes uric acid stones</td>
</tr>
<tr>
<td><strong>Probenecid</strong></td>
<td>- Patients with low uric acid secretion</td>
<td>- Multiple daily dosing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- inffective in renal failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- promotes uric acid stones</td>
</tr>
<tr>
<td><strong>Uricase</strong></td>
<td>- Able to eliminate tophi</td>
<td>- COST</td>
</tr>
<tr>
<td></td>
<td>- Effective in tumour lysis syndrome</td>
<td></td>
</tr>
</tbody>
</table>
<p>Before adding urate-lowering therapy to gout patients, consider the following:</p>
<ul>
<li>Culprit drugs<ul>
<li>thiazide diuretics - increased risk of crystallisation<ul>
<li>some diuretics reduce kidney excretion of urate</li>
</ul>
</li>
<li>cyclosporin, tacrolimus (both immunosuppressants for transplant organ recipients)<ul>
<li>decrease clearance of urate from kidney, cyclosporin &gt; tacrolimus</li>
</ul>
</li>
<li>pyrazinamide, ethambutol (anti-TB)<ul>
<li>pyrazinamide is a strong urate retention agent</li>
<li>ethambutol decreases renal clearance of urate but less than the former</li>
</ul>
</li>
</ul>
</li>
<li>Weak uricosuric indication<ul>
<li>fenofibrate - increases renal clearance of urate</li>
<li>losartan - increases urine pH, urate becomes more soluble</li>
</ul>
</li>
</ul>
<h2 id="Pseudogout"><a href="#Pseudogout" class="headerlink" title="Pseudogout"></a>Pseudogout</h2><p>Deposition of calcium pyrophosphate dihydrate (CPPD) crystals in the joint<br>Calcification of the soft tissues, tendons, bursae</p>
<h1 id="Rheumatoid-Arthritis"><a href="#Rheumatoid-Arthritis" class="headerlink" title="Rheumatoid Arthritis"></a>Rheumatoid Arthritis</h1><p>Most common chronic inflammatory joint disease<br>Females &gt; Males<br>Peak onset - age 50 - 70  </p>
<p>Smoking - strongest risk factor</p>
<p>Autoimmune<br>Gene polymorphisms (gene variants in population)<br>HLA-DR, HLA-DQ, HLA-DP, HLA-DM</p>
<p>Pannus formation at synovium  </p>
<ul>
<li>Increased pressure<ul>
<li>hypoxia in type B synoviocytes (fibroblastic)</li>
<li>Hypoxia inducible factor (HIF1-a) increased</li>
<li>IL-1, TNF in type A synoviocytes (macrophages) stabilise HIF1-a</li>
<li>H1F1-a stimulates Vascular endothelial growth factor (VEGF)</li>
<li>VEGF causes poorly ordered angiogenesis</li>
<li>Cytokine cascade from new endothelial vessels</li>
</ul>
</li>
</ul>
<h2 id="Clinical-Features-1"><a href="#Clinical-Features-1" class="headerlink" title="Clinical Features"></a>Clinical Features</h2><p>Early morning stiffness &gt; 30 minutes<br>Synovitis in 3 or more joints<br>Symptoms last &gt; 6 weeks</p>
<ul>
<li>Viral infections can cause RA-like symptoms that usually resolve by 6 weeks</li>
</ul>
<p>NEED TO EXCLUDE</p>
<ul>
<li>Viral</li>
<li>Psoriatic</li>
<li>SLE</li>
<li>Crystal</li>
</ul>
<p><strong>Early onset OA presentation - looks non-specific</strong></p>
<ul>
<li>local soft tissue inflammation<ul>
<li>carpal tunnel syndrome, bursitis</li>
</ul>
</li>
<li>systemic features<ul>
<li>fatigue</li>
<li>weight loss</li>
<li>fever</li>
<li>myalgia (muscle pain)</li>
</ul>
</li>
</ul>
<h3 id="Joint-distribution-UL"><a href="#Joint-distribution-UL" class="headerlink" title="Joint distribution - UL"></a>Joint distribution - UL</h3><ul>
<li>MCPs</li>
<li>PIPs - DIPs unaffected</li>
<li>Wrists</li>
<li>Elbows</li>
<li>Shoulders</li>
<li>Erosions at:<ul>
<li>Joints of the thumb</li>
<li>1st, 2nd MCP</li>
<li>2nd PIP</li>
<li>Wrist joint</li>
</ul>
</li>
</ul>
<h3 id="Joint-distribution-LL"><a href="#Joint-distribution-LL" class="headerlink" title="Joint distribution - LL"></a>Joint distribution - LL</h3><ul>
<li>Hips</li>
<li>Knees</li>
<li>Ankle</li>
<li>MTPs</li>
</ul>
<h4 id="Typical-RA-deformities-in-the-hand"><a href="#Typical-RA-deformities-in-the-hand" class="headerlink" title="Typical RA deformities in the hand"></a>Typical RA deformities in the hand</h4><p>Due to uncontrolled inflammation - joint &amp; soft tissues damaged</p>
<ul>
<li>ulnar deviation</li>
<li>subluxation at MCPs</li>
<li>Swan neck deformity - DIP extended, PIP flexed</li>
<li>Boutonniere - DIP flexed, PIP extended</li>
</ul>
<h4 id="Spinal-involvement"><a href="#Spinal-involvement" class="headerlink" title="Spinal involvement"></a>Spinal involvement</h4><ul>
<li>Pannus at C1-C2</li>
<li>Atlanto-axial subluxation</li>
<li>Sub-axial subluxation</li>
<li>Potential compression of spinal cord from pannus growth off C1-C2</li>
</ul>
<h4 id="Extra-articular-features-of-RA-outside-joint"><a href="#Extra-articular-features-of-RA-outside-joint" class="headerlink" title="Extra-articular features of RA (outside joint)"></a>Extra-articular features of RA (outside joint)</h4><p>Rheumatoid nodules - most common</p>
<ul>
<li>presence of extra-articular features associated with worse prognosis</li>
<li>Sero-positive (RF, anti-CCP)</li>
<li>Typically occur on elbows<ul>
<li>usually extensor surfaces</li>
<li>pressure areas – olecranon, lateral fingers, heel</li>
<li>not limited, can occur in Achilles tendon, lungs</li>
</ul>
</li>
<li>Late RA, nodules have central necrosis/rim cells/outer pannus</li>
</ul>
<p>Lung disease  </p>
<ul>
<li>Pleural effusions</li>
<li>Pleuritis</li>
<li>Fibrosis</li>
<li>Rheumatoid nodules</li>
</ul>
<p>Heart disease  </p>
<ul>
<li>Pericarditis</li>
<li>Pericardial effusions</li>
</ul>
<p>Eye disease</p>
<ul>
<li>Scleromalacia perforans<ul>
<li>Inflammation of sclera</li>
<li>Thinning &amp; rupture of sclera</li>
</ul>
</li>
<li>Sicca syndrome<ul>
<li>dry eyes</li>
<li>dry mouth</li>
<li>Not everyone with Sicca has Sjogren’s</li>
</ul>
</li>
</ul>
<p>Vasculitis</p>
<ul>
<li>Nail fold infarcts</li>
<li>Vasculitic ulcers</li>
<li>mononeuritis multiplex<ul>
<li>loss of sensory &amp; motor function of individual nerves</li>
</ul>
</li>
</ul>
<p>Felty’s syndrome<br>Occurs in long-standing, seropositive RA</p>
<ul>
<li>Splenomegaly with/without lymphadenopathy</li>
<li>Neutropenia - abnormally few neutrophils</li>
<li>Leg ulcers</li>
<li>Recurrent infections</li>
</ul>
<h4 id="Morbidity-amp-mortality-in-RA"><a href="#Morbidity-amp-mortality-in-RA" class="headerlink" title="Morbidity &amp; mortality in RA"></a>Morbidity &amp; mortality in RA</h4><p>Cardiovascular risk of RA</p>
<ul>
<li>Increased risk of CVE from RA<ul>
<li>Good control of inflammation reduces CVE risk<ul>
<li>methotrexate, biologic agents</li>
</ul>
</li>
<li>Smoking exacerbates CVE</li>
</ul>
</li>
</ul>
<p><u><em>Rest of spine rarely involved</em></u></p>
<h3 id="Diagnostic-tests"><a href="#Diagnostic-tests" class="headerlink" title="Diagnostic tests"></a>Diagnostic tests</h3><p>Autoantibodies</p>
<ul>
<li>RF &amp; anti-CCP</li>
<li>Useful for diagnosis &amp; prognosis</li>
</ul>
<p>Non-specific investigations</p>
<ul>
<li>ESR &amp; CRP</li>
<li>Markers of inflammation – useful for monitoring disease activity</li>
</ul>
<p>Rheumatoid factor (RF)</p>
<ul>
<li>Poor screening test</li>
<li>Low specificity in general population<ul>
<li>false positive in patients &gt; 75 years</li>
</ul>
</li>
<li>Present in infections, other autoimmune diseases</li>
</ul>
<p>Anti-CCP - antibody to cyclic citrullinated protein</p>
<ul>
<li>Highly specific (more specific than RF)</li>
<li>Correlates with RF<ul>
<li>Better than RF in predicting severity of disease<ul>
<li>erosive disease</li>
</ul>
</li>
</ul>
</li>
<li>Early association with RA</li>
<li>HLA-DRB1 associated<ul>
<li>HLA-DRB1*0402 is protective against RA<ul>
<li>enables antigen presentation to CD4 Tcell</li>
</ul>
</li>
<li>Influences development of seropositive RA</li>
<li>Associated with more severe RA, extra-articular manifestations</li>
</ul>
</li>
</ul>
<p>General investigations in RA<br>FBC</p>
<ul>
<li>Normochromic (normal Hb concentration) normocytomic (normal sized RBCs) anaemia – just very little RBCs</li>
<li>Normal WCC</li>
<li>Thrombocytosis - too much platelets (sign of active RA)</li>
</ul>
<p>ESR</p>
<ul>
<li>Increased with disease activity</li>
<li>Increases with age - normal is around half a person’s age</li>
</ul>
<p>CRP</p>
<ul>
<li>acute phase reactant</li>
<li>increases with disease activity, not affected by age</li>
</ul>
<p>Ferritin (protein that stores iron)</p>
<ul>
<li>increases as acute phase reactant</li>
</ul>
<h4 id="Definite-diagnosis-of-RA"><a href="#Definite-diagnosis-of-RA" class="headerlink" title="Definite diagnosis of RA"></a><strong>Definite diagnosis of RA</strong></h4><ul>
<li>Multiple joint involvement with synovitis<ul>
<li>especially small joints of hands, feet</li>
</ul>
</li>
<li>ESR and/or CRP elevated</li>
<li>Positive RF and/or CCP<ul>
<li>Anti-CCP especially</li>
</ul>
</li>
<li>Symptoms &gt; 6 weeks</li>
<li>Need to exclude other diseases</li>
</ul>
<p><u><em>Not all RA patients have anti-CCP, patients with parasitic/mycobacterial diseases may have anti-CCP as well</em></u></p>
<h3 id="X-ray"><a href="#X-ray" class="headerlink" title="X-ray"></a><strong>X-ray</strong></h3><p><strong>L</strong> - loss of joint space - narrowing<br><strong>E</strong> - erosions<br><strong>S</strong> - soft tissue swelling<br><strong>S</strong> - soft bones (osteopenia)  </p>
<p>Early RA in Hands</p>
<ul>
<li>soft tissue swelling</li>
<li>peri-articular osteoporosis</li>
<li>subtle erosions</li>
</ul>
<p>Established RA</p>
<ul>
<li>Punched out “bites” erosion<ul>
<li>chronic, form sclerotic rim when healed</li>
</ul>
</li>
</ul>
<p>Late RA</p>
<ul>
<li>Diffuse cartilage loss by pannus</li>
<li>Diffuse loss of joint space</li>
<li>Erosion of surface cartilage &amp; margins by the pannus</li>
<li>Subchondral cysts - same as OA…</li>
<li>Synovial cyst</li>
</ul>
<p>Hands</p>
<ul>
<li>peri-articular erosion</li>
<li>Subluxation - base of thumb (but not OA)</li>
</ul>
<h3 id="Management-of-RA"><a href="#Management-of-RA" class="headerlink" title="Management of RA"></a>Management of RA</h3><p>Importance of early treatment</p>
<ul>
<li>early damage<ul>
<li>erosion in 2 years</li>
<li>significant BMD loss in 1st year</li>
</ul>
</li>
<li>early disability</li>
</ul>
<p>Aim of treatment</p>
<ul>
<li>Remission or lowered disease activity</li>
<li>No stiffness, synovitis</li>
<li>low ESR/CRP</li>
<li>Symptomatic treatment<ul>
<li>Analgesics</li>
<li>Anti-inflammatory drugs</li>
<li>NSAIDs (COX-2)</li>
<li>Corticosteroids</li>
</ul>
</li>
<li>Begin with methotrexate</li>
<li>2nd DMA after 3 months</li>
<li>Biologic agents after 6 months</li>
</ul>
<h4 id="Methotrexate"><a href="#Methotrexate" class="headerlink" title="Methotrexate"></a>Methotrexate</h4><p>Purine antagonist - prevent RNA/DNA synthesis<br>Acts on dihydrofolate reductase (needed for de novo synthesis of purines)  </p>
<ul>
<li>up to 20mg weekly</li>
<li>folic acid supplements to reduce side effects:<ul>
<li>mouth ulcers</li>
<li>nausea</li>
<li>abnormal liver function - accumulation in liver</li>
<li>Increased infection risk - bone marrow suppression</li>
<li>pneumonitis</li>
<li>fibrosis of lung</li>
</ul>
</li>
<li>monitor FBC, LFT, creatinine</li>
</ul>
<h4 id="Leflunomide"><a href="#Leflunomide" class="headerlink" title="Leflunomide"></a>Leflunomide</h4><p>Pyrimidine antagonist - prevent RNA/DNA synthesis<br>Acts on de novo synthesis pathway for pyrimidines (against dihydroorotate dehydrogenase)</p>
<ul>
<li>Side effects<ul>
<li>alopecia - hair loss/balding</li>
<li>diarrhoea</li>
<li>rash</li>
<li>abnormal liver function</li>
<li>infection risk</li>
<li>cytopenia - reduction of blood cell counts in general</li>
<li>peripheral neuropathy</li>
</ul>
</li>
</ul>
<h4 id="Sulfasalazine"><a href="#Sulfasalazine" class="headerlink" title="Sulfasalazine"></a>Sulfasalazine</h4><p>Used alone in sero-negative arthritis or in combination</p>
<ul>
<li>Anti-inflammatory, 4 - 6 tablets per day<ul>
<li>thought to inhibit NFkb (nuclear factor kappa B)</li>
<li>inhibits granulocyte activation &amp; chemotaxis</li>
<li>inhibits synthesis of IL-1 &amp; IL-2 (monocytes &amp; lymphocytes, respectively)</li>
<li>inhibits lymphocyte proliferation</li>
</ul>
</li>
<li>Side effects<ul>
<li>Rash</li>
<li>nausea</li>
<li>headache</li>
<li>rare but serious - neutropenia</li>
<li>GI toxicity</li>
<li>dizziness</li>
<li>depression</li>
<li>thrombocytopenia</li>
<li>reversible infertility in males</li>
</ul>
</li>
</ul>
<h4 id="Hydroxychloroquine"><a href="#Hydroxychloroquine" class="headerlink" title="Hydroxychloroquine"></a>Hydroxychloroquine</h4><p>used in combination</p>
<ul>
<li>Anti-malarial but has anti-inflammatory effects<ul>
<li>targets lysosomes<ul>
<li>prevents activation of innate immune cells</li>
<li>stops presentation to lymphocytes</li>
</ul>
</li>
</ul>
</li>
<li>Side effects - time limited use due to toxicity<ul>
<li>GI toxicity</li>
<li>rash</li>
<li>rare retinal complication - chloroquine retinopathy<ul>
<li>macular lesion</li>
<li>reduction in visual acuity</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="Biologic-agents"><a href="#Biologic-agents" class="headerlink" title="Biologic agents"></a>Biologic agents</h4><ul>
<li>TNF inhibitors (anti-TNF antibodies)<ul>
<li>infliximab</li>
<li>etanercept</li>
<li>adalumimab</li>
<li>golimumab</li>
<li>certolizumab<ul>
<li>TNF needed for granuloma formation</li>
<li>risk of reactivating latent TB  <blockquote>
<p>Side effects of TNF inhibitors</p>
<ul>
<li>Injection site reactions common</li>
<li>Infections - especially respiratory tract</li>
<li>Reactivation of latent infections e.g. TB</li>
<li>Demyelination</li>
<li>Drug-induced SLE</li>
</ul>
</blockquote>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<ul>
<li>IL-6 antibodies<ul>
<li>tocilizumab<ul>
<li>blocking of IL-6 prevents JAK-STAT3 intracellular signalling - reducing cellular survival &amp; proliferation<blockquote>
<p>Side effects</p>
<ul>
<li>abnormal liver function</li>
<li>neutropenia</li>
<li>Increased infection risk - cellulitis, others</li>
<li>Increased cholesterol (HDL &amp; LDL)</li>
</ul>
</blockquote>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<ul>
<li><p>Anti-CD20 (B-cell blocker)</p>
<ul>
<li>rituximab<ul>
<li>induces ADCC<blockquote>
<p>Side effects</p>
<ul>
<li>Pulmonary toxicity - rituximab-induced ILD</li>
</ul>
</blockquote>
</li>
</ul>
</li>
</ul>
</li>
<li><p>CTLA-4 antibody - prevents co-stimulation between T cell and APCs</p>
<ul>
<li>abatacept<ul>
<li>Blocks CD80/86 on APC, T-cells cannot activate &amp; proliferate</li>
<li>Inhibits T-cell mediated cytokine release<blockquote>
<p>Side effects</p>
<ul>
<li>immunosuppression - increased infections</li>
<li>hypersensitivity reactions</li>
<li>Respiratory function worsening in COPD patients</li>
<li>headache</li>
</ul>
</blockquote>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><u>Benefits of biologic agents</u><br>Good response from patients - increased remission rates<br>Reduced radiological damage<br>Normalisation of ESR, CRP<br>Reduced CVEs  </p>
<h4 id="DMARDs"><a href="#DMARDs" class="headerlink" title="DMARDs"></a>DMARDs</h4><p>Target immune cells &amp; inflammatory pathways<br>Slow-acting<br>Long term outcome - slow progression of disease</p>
<p><u>Conventional DMARDs</u><br>Methotrexate &amp; leflunomide (purine, pyrimidine synthesis inhibition respectively)<br>Sulfasalazine (anti-inflammatory, acts on NF-kb)<br>Hydroxychloroquine (anti-inflammatory)</p>
<p><u>Biological DMARDs</u><br>TNF-a inhibitors - infliximab<br>IL-6 inhibitors - tocilizumab<br>CD20 blocker (block B-cells) - rituximab<br>CTLA4 inhibitor (prevent co-stimulation between T-cell &amp; APC) - abatacept</p>
<h1 id="Psoriatic-arthritis"><a href="#Psoriatic-arthritis" class="headerlink" title="Psoriatic arthritis"></a>Psoriatic arthritis</h1><p>Joints involved</p>
<ul>
<li>Vertebrae</li>
<li>Sacroiliac joint</li>
<li>Hand<ul>
<li>Asymmetrical</li>
<li>All joints of the hand</li>
</ul>
</li>
<li>Ankle</li>
<li>Foot</li>
</ul>
<h1 id="Systemic-lupus-erythematosus"><a href="#Systemic-lupus-erythematosus" class="headerlink" title="Systemic lupus erythematosus"></a>Systemic lupus erythematosus</h1><p>Autoimmune disease<br>Females of childbearing age &gt; Males (9:1)</p>
<h3 id="Management-of-SLE"><a href="#Management-of-SLE" class="headerlink" title="Management of SLE"></a>Management of SLE</h3><p>Hydroxychloroquine (anti-inflammatory)<br>Short term prednisone (if not controlled with NSAIDs)<br>Azathiprine or methotrexate  </p>
<p>Diffuse proliferative glomerulonephritis<br>High dose steroids + mycophenolate (immunosuppressant)</p>
<h1 id="Specific-auto-antibodies"><a href="#Specific-auto-antibodies" class="headerlink" title="Specific auto-antibodies"></a>Specific auto-antibodies</h1><h3 id="RA"><a href="#RA" class="headerlink" title="RA"></a>RA</h3><ul>
<li>Inflammatory markers<ul>
<li>ESR</li>
<li>CRP</li>
</ul>
</li>
<li>RF - in association with anti-CCP</li>
<li><strong>Anti-CCP</strong></li>
<li>Others (can be positive, usually negative)<ul>
<li>ANA</li>
<li>ENA (SSA, SSB)</li>
<li>dsDNA</li>
</ul>
</li>
</ul>
<h3 id="SLE"><a href="#SLE" class="headerlink" title="SLE"></a>SLE</h3><ul>
<li>ANA + (non-specific)</li>
<li>ENA tests<ul>
<li><strong>Smith + (most specific)</strong></li>
<li>SSA + (also present in Sjogren’s, SLE, RA)</li>
<li>SSB +</li>
</ul>
</li>
<li><strong>dsDNA + (specific, positive in 60% patients)</strong></li>
</ul>
<p><u><em>RF present, but non-specific</em></u>  </p>
<h3 id="Scleroderma"><a href="#Scleroderma" class="headerlink" title="Scleroderma"></a>Scleroderma</h3><p>Scl-70 - diffuse scleroderma<br>Anti-centromere - limited scleroderma  </p>
<h3 id="Sjogren’s"><a href="#Sjogren’s" class="headerlink" title="Sjogren’s"></a>Sjogren’s</h3><p>ENA - SSA, SSB  </p>

      
    </div>
    <footer>
      
        
        
        
      
      <div class="clearfix"></div>
    </footer>
  </div>
</article>


<section id="comment">
  <h1 class="title">comment</h1>

  
</section>

</div></div>
    <aside id="sidebar" class="alignright">
  

  
<div class="widget tag">
  <h3 class="title">Tags</h3>
  <ul class="entry">
  
    <li><a href="/blog/tags/about/">about</a><small>1</small></li>
  
    <li><a href="/blog/tags/self/">self</a><small>1</small></li>
  
    <li><a href="/blog/tags/stage-1/">stage 1</a><small>1</small></li>
  
    <li><a href="/blog/tags/theme/">theme</a><small>1</small></li>
  
  </ul>
</div>

</aside>
    <div class="clearfix"></div>
  </div>
  <footer id="footer" class="inner"><div class="alignleft">
  
  &copy; 2016 ymtang
  
</div>
<div class="clearfix"></div></footer>
  <script src="//ajax.googleapis.com/ajax/libs/jquery/2.0.3/jquery.min.js"></script>
<script src="/blog/js/jquery.imagesloaded.min.js"></script>
<script src="/blog/js/gallery.js"></script>




<link rel="stylesheet" href="/blog/fancybox/jquery.fancybox.css" media="screen" type="text/css">
<script src="/blog/fancybox/jquery.fancybox.pack.js"></script>
<script type="text/javascript">
(function($){
  $('.fancybox').fancybox();
})(jQuery);
</script>

</body>

